CollPlant's Reverse Share Split: A New Strategy for Nasdaq Compliance

CollPlant Implements Reverse Share Split for Nasdaq Compliance

On September 1, 2026, CollPlant Biotechnologies Ltd. (Nasdaq: CLGN), a pioneering company in the realm of regenerative and aesthetic medicine, announced its decision to conduct a reverse share split. The Board of Directors authorized this significant move, which will see a transformation of every ten shares into one ordinary share. This change is set to take effect on September 4, 2026, coinciding with the opening of the Nasdaq Capital Market.

The Reason Behind the Decision

The motivation for this reverse split is rooted in a strategic plan devised by the company to maintain its listing on the Nasdaq exchange. By consolidating shares, CollPlant aims to increase its share price to comply with the Nasdaq's minimum bid price requirement—a threshold that is essential to sustain its public listing and investor confidence.

This initiative follows an Extraordinary General Meeting held on August 18, 2026, where shareholders expressed their support for this plan. The decision underscores a commitment to long-term viability and enhancing stakeholder value amidst challenges inherent in the biotechnology sector.

Understanding the Share Split Process

In this reverse split, shareholders will notice a reduction in the overall number of ordinary shares they hold, but their ownership percentage in CollPlant will remain unchanged. It is important to note that fractional shares will be rounded up, ensuring that no shareholder will be left with less than one full share post-split.

Moreover, adjustments will be made to the per share exercise prices and the number of shares available through outstanding warrants and options, effectively syncing all shareholding mechanisms with the new share structure. The new CUSIP number for these ordinary shares will be M2R51X124, marking this transition clearly for investors and market participants.

Impacts on Shareholders

Shareholders holding their shares in book-entry form or through banks and brokerage firms need not take any action concerning the reverse split. However, for those possessing physical share certificates, detailed instructions will be provided by CollPlant’s transfer agent, Computershare Inc., on how to exchange their existing certificates for the new adjusted amount.

CollPlant’s Vision Going Forward

CollPlant is not only taking steps to restructure its shareholding but is also advancing in the field of regenerative medicine. The company is known for its innovative products that utilize recombinant human collagen (rhCollagen), enabling breakthroughs in tissue repair and medical aesthetics. Additionally, CollPlant is on track to finalize its acquisition of LightSolver Ltd., an Israeli deep-tech firm focused on a revolutionary computing architecture using lasers.

This strategic move will potentially enhance CollPlant's capabilities in bioprinting and expand its market reach, aligning with its vision to lead in tissue manufacturing and regenerative therapies. As the company navigates through a challenging economic landscape, these actions are pivotal in positioning itself for sustainable growth and innovation.

CollPlant remains optimistic, reflecting its ongoing commitment to advancing healthcare solutions. Stakeholders are encouraged to stay informed as the company progresses through these structural and strategic shifts. More information can be found on their official website, where they provide regular updates and additional resources relevant to the upcoming changes.

Conclusion

Ultimately, CollPlant's reverse share split is a calculated move aimed at sustaining its Nasdaq listing and invigorating the company's market presence. By consolidating shares, CollPlant not only takes a proactive step towards compliance but also reassures investors of its commitment to maintaining strong corporate governance and a robust financial standing.